Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer, Inc. (Nasdaq: SEER) has appointed Rachel Haurwitz, Ph.D., CEO of Caribou Biosciences, to its Board of Directors effective November 8, 2021. Haurwitz's extensive experience in genome editing is expected to bolster Seer's mission in proteomics. David Singer will step down from the board, marking a significant leadership transition. The addition of Haurwitz, a recognized figure in the biotechnology field, reflects Seer’s commitment to advancing its innovative Proteograph technology aimed at enhancing biological insights.
Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT. The company is known for its innovative Proteograph™ Product Suite, designed for advanced proteomic analysis. This system utilizes proprietary nanoparticles and automation to facilitate in-depth research quickly and efficiently. The results and details will be accessible via Seer’s investor website.
Seer, a life sciences company specializing in proteomics, announced its participation in the Morgan Stanley Global Healthcare Conference. The virtual fireside chat is scheduled for September 9 at 9:30 a.m. Pacific Time. A live webcast will be accessible on Seer's investor website, with an archived replay available post-conference. Seer’s Proteograph Product Suite provides deep proteomic analysis using innovative technology to enhance research capabilities across various labs. This product is intended for research use only and not for diagnostic procedures.
Seer, Inc. (Nasdaq: SEER) reported significant growth in Q2 2021, with revenues surging to $1.3 million from $71,000 in Q2 2020, driven by sales of the Proteograph Product Suite. The company booked initial revenue and expanded its customer base, including its first international client, while entering the Chinese market through a partnership with Enlight Medical. However, operating expenses increased to $17.4 million, resulting in a net loss of $16.6 million. As of June 30, 2021, Seer held approximately $518 million in cash and investments.
Seer (NASDAQ: SEER) partnered with Enlight Medical to distribute its Proteograph Product Suite in China. This collaboration aims to enhance access to Seer’s innovative proteomics platform in one of the world's fastest-growing life sciences markets. The partnership enables Enlight Medical to leverage its industry experience and connections to facilitate sales and marketing. Seer’s Proteograph technology targets biomarker discovery, essential for research in oncology and other diseases. This agreement is expected to accelerate Seer’s commercial presence in China, meeting the rising healthcare demands in the region.
Seer, Inc. (Nasdaq: SEER) will announce its Q2 2021 financial results on August 12, 2021, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET. Live audio will be available on Seer’s investor website, with replays following the event. The company is known for its Proteograph Product Suite, designed for deep proteomic analysis, revolutionizing research with easy-to-use tools for labs. Seer emphasizes that the Proteograph is for research only and not for diagnostics.
Seer, Inc. (Nasdaq: SEER) reported Q1 2021 financial results, revealing a revenue decrease to $62,000 from $177,000 in Q1 2020, attributed to diminished activity linked to an NIH grant. The company's operating expenses surged to $16.6 million, a significant rise from $6.0 million the previous year, mainly due to increased employee costs and product development expenses. The net loss widened to $16.4 million compared to $5.5 million in the prior year. The company maintained a robust cash position of approximately $531 million as of March 31, 2021.
Seer, a life sciences company known for its innovative proteomics platform, announced participation in the BofA Securities 2021 Healthcare Conference. The event will take place virtually on May 13 at 10:15 a.m. PT and will feature a fireside chat with management. Investors can access the live webcast through the Investor section of Seer’s website, with an archived replay available afterward. Seer's Proteograph Product Suite offers advanced, unbiased proteomic analysis, designed for use in various laboratories.
Seer, a life sciences company, will report its Q1 2021 financial results after the market closes on May 10, 2021. The management team will host a conference call starting at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live audio webcast on Seer’s website, with an archived replay available post-event. Seer's focus is on advancing proteomics through its Proteograph™ Product Suite, designed for deep, unbiased analysis in life sciences research.
Seer has entered a non-exclusive agreement with SCIEX to combine their technologies, enhancing proteomics workflows for diverse laboratories. This partnership integrates SCIEX's mass spectrometry with Seer's Proteograph Product Suite, facilitating unbiased and deep proteomics studies at scale. The Proteograph system, featuring engineered nanoparticles and advanced automation, aims to accelerate research by providing comprehensive protein analysis with unprecedented sensitivity and speed. Both companies anticipate future collaborations to further innovate in proteomics.